Clinical Drug Investigation

, Volume 20, Issue 2, pp 67–79

Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia

The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study
  • Tineke J. Smilde
  • Mieke D. Trip
  • Hub Wollersheim
  • Sanne van Wissen
  • John J. P. Kastelein
  • Anton F. H. Stalenhoef
Clinical Use


Objective: Hypercholesterolaemia is strongly associated with increased vessel wall thickness as measured by ultrasound. The question is whether aggressive cholesterol lowering with high-dose atorvastatin can alter intima media thickening to a greater extent than conventional therapy in patients with familial hypercholesterolaemia (FH). The baseline characteristics of a double-blind, randomised trial are described to determine whether two active treatments (high-dose atorvastatin 80mg versus conventional dose simvastatin 40mg), administered over a period of 2 years, may retard the process of intima media thickening in the carotid and femoral arteries of patients with FH.

Design and Patients: 325 patients with FH were randomised. Patients entered an 8-week placebo period in which all lipid-lowering medication was discontinued. Thereafter, baseline measurements of lipoprotein parameters and intima media thickness (IMT) of carotid and femoral artery were performed.

Results: Baseline low density lipoprotein (LDL) cholesterol (±SD) levels were 8.11 ± 1.92 mmol/L (312 ± 73 mg/dl) in men and 8.22 ± 1.91 mmol/L (316 ± 73 mg/dl) in women, respectively. Mean posterior wall IMT in the left common carotid artery (CCA) was significantly greater in men (0.94 ± 0.29mm) compared with women (0.85 ± 0.20) [p < 0.05]. A similar difference was found for the internal carotid artery (ICA). In the carotid bifurcation, IMT was 1.20 ± 0.50mm in men and 1.1 ± 0.54mm in women. The IMT of the common femoral artery (CFA) was 2.03 ± 0.88mm in men with cardiovascular disease (CVD) and 1.63 ± 0.70mm in men without CVD (p < 0.05). Strikingly, plaques were present in all men and 95% of the women with CVD. The cholesterol-year score and HDL cholesterol levels partially explained the variation in IMT in the carotid bifurcation, whereas gender and smoking contributed to the variation in IMT in the CFA in this group of patients.

Conclusion: The patients participating in the Atorvastatin and Simvastatin on Atherosclerosis Progression (ASAP) trial constitute the largest well-documented FH population exhibiting marked increases in IMT of both carotid and femoral arteries and a very high prevalence of plaques, indicating extreme CVD risk. Since lipid-lowering therapy provides the highest benefit in precisely such patients, the ASAP trial will help assess whether aggressive LDL cholesterol intervention leads to retardation of subclinical atherosclerosis progression, as estimated with ultrasonographically assessed IMT.


  1. 1.
    Pignoli P, Tremoli E, Poli A, et al. Intimai plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399–406PubMedCrossRefGoogle Scholar
  2. 2.
    Okin PM, Roman MJ, Devereux RB, et al. Association of carotid atherosclerosis with electrocardiographic myocardial ischemia and left ventricular hypertrophy. Hypertension 1996; 28: 3–7PubMedCrossRefGoogle Scholar
  3. 3.
    Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991; 11: 1245–9PubMedCrossRefGoogle Scholar
  4. 4.
    Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations; associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991; 134:250–6PubMedGoogle Scholar
  5. 5.
    O’Leary DH, Polak JF, Wolfson SKJ, et al.Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke 1991; 22: 1155–63PubMedCrossRefGoogle Scholar
  6. 6.
    Bond MG, Barnes RW, Riley WA, et al. High-resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities Study (ARIC). Am Soc Neuroimag 1991; 68-73Google Scholar
  7. 7.
    Poli A, Tremoli E, Colombo A, et al. Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients. A new model for the quantitation and follow-up of pre clinical atherosclerosis in living human subjects. Atherosclerosis 1988; 70: 253–61PubMedCrossRefGoogle Scholar
  8. 8.
    Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: a case control study. Circulation 1990; 82: 1230–42PubMedCrossRefGoogle Scholar
  9. 9.
    Salonen R, Haapanen A, Salonen JT. Measurement of intima-media thickness of common carotid arteries with high-resolution B-mode ultrasonography: inter- and intraobserver variability. Ultrasound Med Biol 1991; 17: 225–30PubMedCrossRefGoogle Scholar
  10. 10.
    Persson J, Stavenow L, Wikstrand J, et al. Non invasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb 1992; 12: 261–6PubMedCrossRefGoogle Scholar
  11. 11.
    Touboul PJ, Prati P, Scarabin PY, et al. Use of monitoring software to improve the measurement of carotid wall thickness by B-mode imaging. J Hypertens Suppl 1992; 10: S37–S41PubMedCrossRefGoogle Scholar
  12. 12.
    Bots ML, Mulder PG, Hofman A, et al. Reproducibility of carotid vessel wall thickness measurements. The Rotterdam Study. J Clin Epidemiol 1994; 47: 921–30PubMedCrossRefGoogle Scholar
  13. 13.
    Smilde TJ, Wollersheim H, van Langen H, et al. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin Sci 1997; 317-24Google Scholar
  14. 14.
    Furberg CD, Borhani NO, Byington RP, et al. Calcium antagonist and atherosclerosis. Multicenter Isradipine/Diuretic Atherosclerosis Study. Am J Hematol 1993; 6: 24S–29SGoogle Scholar
  15. 15.
    Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. A randomized, controlled clinical trial. Ann Intern Med 1996; 124:548–56PubMedGoogle Scholar
  16. 16.
    Kroon AA, Asten van WNJC, Stalenhoef AFH. Effects of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996; 125: 945–54PubMedGoogle Scholar
  17. 17.
    Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and 4-year reduction of intima-media thickness measured by ultrasound. Circulation 1993; 88: 20–8PubMedCrossRefGoogle Scholar
  18. 18.
    Furberg CD, Adams HP, Applegate WB, et al. for the Asymptomatic Carotid Artery Progression Study (ACAPS) research group. Effect of Lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994: 90: 1679–87PubMedCrossRefGoogle Scholar
  19. 19.
    Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455–9PubMedCrossRefGoogle Scholar
  20. 20.
    Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758–64PubMedCrossRefGoogle Scholar
  21. 21.
    Mack WJ, Selzer RH, Hodis HN, et al. One year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993; 24: 1779–83PubMedCrossRefGoogle Scholar
  22. 22.
    Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Circulation 1993; 88: 20–8PubMedCrossRefGoogle Scholar
  23. 23.
    Mack WJ, Hodis HN, Pogoda JM, et al. Reduction of carotid artery intima-media thickness with lipid lowering therapies: a comparison of two clinical trials. J Am Coll Cardiol 1993; 21Suppl. A: 166AGoogle Scholar
  24. 24.
    Groot de A, Jukema JW, Boven van AJ, et al. on behalf of the REGRESS study group. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the regression growth evaluation statin study. Am J Cardiol 1995; 76: 40C–46CPubMedCrossRefGoogle Scholar
  25. 25.
    Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familia hypercholesterolemia. Ultrasound measurement of intima-media thickness in the common carotid artery. Arterioscl Thromb 1992; 12: 70–7PubMedCrossRefGoogle Scholar
  26. 26.
    Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb 1993; 13: 1404–11PubMedCrossRefGoogle Scholar
  27. 27.
    Smilde TJ, van den Berkmortel FWPJ, Boers HJ, et al. Carotid and femoral wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyper-homocysteinemia. Arterioscler Thromb Vasc Biol 1998; 18: 1958–63PubMedCrossRefGoogle Scholar
  28. 28.
    Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Carotid intima media thickness and plaque in patients with familial hypercholesterolemia mutations and control subjects. Eur J Clin Invest 1998; 28: 971–9PubMedCrossRefGoogle Scholar
  29. 29.
    Sidhu PS, Naoumova RP, Maher VMG, et al. The extracranial carotid artery in familial hypercholesterolemia: relationship of intimal-media thickness and plaques morphology with plasma lipids and coronary heart disease. J Cardiovasc Risk 1996; 3: 61–7PubMedCrossRefGoogle Scholar
  30. 30.
    Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007–12PubMedCrossRefGoogle Scholar
  31. 31.
    Schectman G, Hiatt J, Pharm D. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197–204PubMedCrossRefGoogle Scholar
  32. 32.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol owering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  33. 33.
    Pedersen TR, Olsson AG, Faergeman O, et al. for The Scandinavian Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453–60PubMedCrossRefGoogle Scholar
  34. 34.
    Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25–60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678–82PubMedCrossRefGoogle Scholar
  35. 35.
    Demacker PNM, Hijmans AG, Vos-Jansen HE, et al. A study of the use of polyethylene glycol in estimating cholesterol in high density lipoprotein. Clin Chem 1980; 26: 1775–9PubMedGoogle Scholar
  36. 36.
    Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultra fast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1066–74PubMedCrossRefGoogle Scholar
  37. 37.
    Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994; 236: 567–73PubMedCrossRefGoogle Scholar
  38. 38.
    Crouse JR, Craven TE, Hagaman AP, et al. Association of coronary disease with segment-specific intimal-medial thickening of extracranial carotid artery. Circulation 1995; 92: 1141–7PubMedCrossRefGoogle Scholar
  39. 39.
    Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96:1432–7PubMedCrossRefGoogle Scholar
  40. 40.
    Lekakis JP, Papamichael CM, Cimponeriu AT, et al. Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis. Am J Cardiol 2000; 85: 949–52PubMedCrossRefGoogle Scholar
  41. 41.
    O’Leary DH, Polak JF, Kronmal RA, et al. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14–22PubMedCrossRefGoogle Scholar
  42. 42.
    Chambless LE, Heiss G, Folsom AAR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987–1993. Am J Epidemiol 1997; 146: 483–94PubMedCrossRefGoogle Scholar
  43. 43.
    Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262–9PubMedGoogle Scholar
  44. 44.
    Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults Summary of the second report of the national cholesterol education program (NCEP) expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II) JAMA 1993; 269: 3015-23Google Scholar
  45. 45.
    Wood D, De Backer G, Faergeman O, et al. together with members of the task force. Task force report. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199–270PubMedCrossRefGoogle Scholar
  46. 46.
    Marais AD, Firth JC, Bateman ME, et al. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia. Arterioscl Thromb Vasc Biol 1997; 17: 1527–31PubMedCrossRefGoogle Scholar
  47. 47.
    Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the curves study). Am J Cardiol 1998; 81: 582–7PubMedCrossRefGoogle Scholar
  48. 48.
    Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995; 6: 386–8PubMedCrossRefGoogle Scholar
  49. 49.
    The Post Coronary Artery Bypass Graft trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass graft. N Engl J Med 1997; 336: 153–62CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Tineke J. Smilde
    • 1
  • Mieke D. Trip
    • 2
  • Hub Wollersheim
    • 1
  • Sanne van Wissen
    • 2
  • John J. P. Kastelein
    • 2
  • Anton F. H. Stalenhoef
    • 1
  1. 1.Department of Medicine, Division of General Internal Medicine 541University Medical Center Nijmegen, University Hospital NijmegenNijmegenThe Netherlands
  2. 2.Department of Vascular MedicineAcademic Medical CenterAmsterdamThe Netherlands

Personalised recommendations